Indication
Stage II Adult Lymphoblastic Lymphoma
3 clinical trials
19 products
6 drugs
Clinical trial
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)Status: Active (not recruiting), Estimated PCD: 2020-03-31
Product
BortezomibDrug
cyclophosphamideProduct
CytarabineProduct
DaunorubicinProduct
DexamethasoneProduct
DoxorubicinProduct
EtoposideProduct
HydrocortisoneProduct
IfosfamideProduct
LeucovorinProduct
MercaptopurineProduct
MethotrexateProduct
PegaspargaseProduct
ThioguanineDrug
VincristineClinical trial
A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell TransplantStatus: Completed, Estimated PCD: 2024-02-02
Clinical trial
Rituximab For Prevention Of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT)Status: Terminated, Estimated PCD: 2012-12-19
Drug
rituximabDrug
tacrolimusProduct
Anti-thymocyte globulinProduct
FludarabineDrug
busulfanProduct
Immunosuppressive therapy